Daily Roundup

CCA.ASX ALC.ASX BOT.ASX CDA.ASX EYE.ASX

Strong Q3 Capped by Solid Results Across the Board

Change Financial delivered a standout quarter, reporting record customer receipts, increased revenue, and a near doubling of Underlying EBITDA. The company's Vertexon platform continues to scale, with active cards now topping 119,000 - a 70% jump from the prior year.

Elsewhere, Alcidion Group wrapped up a productive Q3, generating positive operating cash flow of $1.7 million on the back of $14.5 million in cash receipts. The healthcare tech firm also secured a major contract as the preferred provider for University Hospital Sussex's new electronic patient record (EPR) system.

Botanix Pharmaceuticals saw total prescriptions for its Sofdra product climb 5% in Q3, though a temporary dip in average gross-to-net yield led to a decline in net revenue. The company raised $45 million through a capital raise and renegotiated its API supply agreement to defer $15 million in future purchases.

Codan provided an upbeat trading update, forecasting its Communications business will achieve revenue growth at the top end of its 15-20% guidance range for the full year. The segment's profit margin is also now expected to reach 30% in FY26, outpacing the previous 30% target.

Rounding out the day's news, Nova Eye Medical reported a 23% surge in quarterly sales to $5.8 million, fueled by continued momentum in the US and initial traction in China. The company also made significant strides in improving its EBITDA position, cutting the loss to just $75,000.

Overall, it was a well-rounded day for these ASX-listed companies, with several delivering impressive operational and financial results to cap off a strong quarter.